Education
About Us
Working with TipRanks
Follow Us
Heidi Fields Insider Profile
4 Followers
Heidi Fields, Director at Agilent, holds 19.50K shares in Phathom Pharmaceuticals (Ticker: PHAT), holds 56.65K shares in Agilent (Ticker: A), holds 0.00 shares in Icosavax (Ticker: ICVX).
Profitable Transactions
3 out of 13 Profitable Transactions
Average Return
-16.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Heidi Fields holds in companies
Most Profitable Insider Trade
The most profitable trade made by Heidi Fields
Heidi Fields's Trading History
Agilent
Mar 19, 2024
Director
Uninformative Buy
247.47K
$7.18M
Phathom Pharmaceuticals
May 24, 2024
Director
Uninformative Buy
―
$98.67K
Icosavax
Feb 20, 2024
―
Uninformative Sell
―
$0.00
Financial Engines
Jul 23, 2018
―
Uninformative Sell
958.05K
$0.00
Avanos Medical
Jan 06, 2021
Director
Uninformative Buy
―
$439.75K
List of latest transactions for each holding click on a transaction to see Heidi Fields's performance on stock
You May Also Like
Heidi Fields insider profile FAQ
What is the percentage of profitable transactions made by Heidi Fields?
The percentage of profitable transactions made by Heidi Fields is 23%.
What is the average return per transaction made by Heidi Fields?
The average return per transaction made by Heidi Fields is -16.80%.
What stocks does Heidi Fields hold?
Heidi Fields holds: A, PHAT, ICVX, FNGN, AVNS stocks.
What was Heidi Fields’s latest transaction?
Heidi Fields latest transaction was an Uninformative Buy of ―.
What was Heidi Fields's most profitable transaction?
Heidi Fields’s most profitable transaction was an Informative Sell of A stock on October 1, 2014. The return on the trade was 15.10%.
What is Heidi Fields's role in Agilent?
Heidi Fields's role in Agilent is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.